| 1 |
King AL, Roche KN, Leeper HE, Vera E, Mendoza T, Mentges K, Acquaye-Mallory AA, Adegbesan KA, Boris L, Burton E, Choi A, Grajkowska E, Kunst T, Levine J, Lollo N, Miller H, Panzer M, Penas-Prado M, Pillai V, Polskin L, Reyes J, Sahebjam S, Stockdill ML, Theeler BJ, Wu J, Gilbert MR, Armstrong TS. Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial. J Neurooncol 2023;:1-9. [PMID: 36884201 DOI: 10.1007/s11060-023-04271-0] [Reference Citation Analysis]
|
| 2 |
King AL, Roche KN, Leeper HE, Vera E, Mendoza T, Mentges K, Acquaye AA, Adegbesan K, Boris L, Burton E, Choi A, Grajkowska E, Kunst T, Levine J, Lollo N, Miller H, Panzer M, Penas-Prado M, Pillai V, Polskin L, Reyes J, Sahebjam S, Stockdill M, Theeler BJ, Wu J, Gilbert MR, Armstrong TS. Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trial. Res Sq 2023:rs. [PMID: 36789426 DOI: 10.21203/rs.3.rs-2522094/v1] [Reference Citation Analysis]
|
| 3 |
Zhang Z, Yin J, Yue Y, Su Y, Jiang H. Assessing clinical trial failure risk factors and reasons in gastric cancer. BMC Gastroenterol 2022;22:496. [PMID: 36451088 DOI: 10.1186/s12876-022-02592-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Melhem JM, Detsky J, Lim-Fat MJ, Perry JR. Updates in IDH-Wildtype Glioblastoma. Neurotherapeutics 2022;19:1705-23. [PMID: 35641844 DOI: 10.1007/s13311-022-01251-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Shah HA, Mishra A, Gouzoulis MJ, Ben-Shalom N, D'Amico RS. Analysis of factors leading to early termination in glioblastoma-related clinical trials. J Neurooncol 2022. [PMID: 35648307 DOI: 10.1007/s11060-022-04039-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Simonelli M, Persico P, Capucetti A, Carenza C, Franzese S, Lorenzi E, Dipasquale A, Losurdo A, Giordano L, Pessina F, Navarria P, Politi LS, Mavilio D, Locati M, Della Bella S, Santoro A, Bonecchi R. Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes. Neurooncol Adv 2021;3:vdab160. [PMID: 34901858 DOI: 10.1093/noajnl/vdab160] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 7 |
Zreik J, Kerezoudis P, Alvi MA, Yolcu YU, Kizilbash SH. Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database. Front Oncol 2021;11:746844. [PMID: 34858822 DOI: 10.3389/fonc.2021.746844] [Reference Citation Analysis]
|
| 8 |
Gao YK, Kuksis M, Id Said B, Chehade R, Kiss A, Tran W, Sickandar F, Sahgal A, Warner E, Soliman H, Jerzak KJ. Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single-Center Retrospective Study. Oncologist 2021;26:e1951-61. [PMID: 34506676 DOI: 10.1002/onco.13965] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Lee E, Wen P. Gender and sex disparity in cancer trials. ESMO Open 2020;5:e000773. [PMID: 32816862 DOI: 10.1136/esmoopen-2020-000773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 10 |
Lee EQ, Selig W, Meehan C, Bacha J, Barone A, Bloomquist E, Chang SM, de Groot JF, Galanis E, Hassan I, Kalidas C, Khasraw M, Kvedar JC, Lassman AB, Puduvalli V, Sahebjam S, Schwamm LH, Tamir S, Welch M, Yung WKA, Zadeh G, Arons D, Wen PY. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro Oncol 2021;23:1252-60. [PMID: 33822177 DOI: 10.1093/neuonc/noab082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Lee EQ. Clinical Trial Considerations in Neuro-oncology. Curr Treat Options Oncol 2021;22:78. [PMID: 34213625 DOI: 10.1007/s11864-021-00875-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 12 |
Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro Oncol 2020;22:601-12. [PMID: 31974566 DOI: 10.1093/neuonc/noaa015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 13 |
Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, Choulier L. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers (Basel) 2021;13:1795. [PMID: 33918704 DOI: 10.3390/cancers13081795] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 14 |
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 2020;22:1073-113. [PMID: 32328653 DOI: 10.1093/neuonc/noaa106] [Cited by in Crossref: 268] [Cited by in F6Publishing: 279] [Article Influence: 134.0] [Reference Citation Analysis]
|
| 15 |
Skaga E, Skretteberg MA, Johannesen TB, Brandal P, Vik-Mo EO, Helseth E, Langmoen IA. Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply? Neurooncol Adv 2021;3:vdab008. [PMID: 33665615 DOI: 10.1093/noajnl/vdab008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Lamba N, Chukwueke UN, Smith TR, Ligon KL, Aizer A, Reardon DA, Iorgulescu JB. Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncol 2020;6:1972-4. [PMID: 33090181 DOI: 10.1001/jamaoncol.2020.4937] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 17 |
Ventz S, Bacallado S, Rahman R, Tolaney S, Schoenfeld JD, Alexander BM, Trippa L. The effects of releasing early results from ongoing clinical trials. Nat Commun 2021;12:801. [PMID: 33547324 DOI: 10.1038/s41467-021-21116-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 18 |
Hoffman SE, Al Abdulmohsen SA, Gupta S, Hauser BM, Meredith DM, Dunn IF, Bi WL. Translational Windows in Chordoma: A Target Appraisal. Front Neurol 2020;11:657. [PMID: 32733369 DOI: 10.3389/fneur.2020.00657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Liu Y, Wasilewski A, Mohile NA. Disparities in patient enrollment on glioblastoma clinical trials. CNS Oncol 2020;9:CNS59. [PMID: 32603616 DOI: 10.2217/cns-2020-0008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 20 |
Snyder JM, Pawloski JA, Poisson LM. Developing Real-world Evidence-Ready Datasets: Time for Clinician Engagement. Curr Oncol Rep 2020;22:45. [PMID: 32297007 DOI: 10.1007/s11912-020-00904-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Martin-McGill KJ, Marson AG, Tudur Smith C, Young B, Mills SJ, Cherry MG, Jenkinson MD. Ketogenic diets as an adjuvant therapy for glioblastoma (KEATING): a randomized, mixed methods, feasibility study. J Neurooncol 2020;147:213-27. [PMID: 32036576 DOI: 10.1007/s11060-020-03417-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 22 |
Rogers JL, Acquaye A, Vera E, Bates A, Wen PY, Armstrong TS. Provider-reported challenges and barriers to referring patients to neuro-oncology clinical trials: a report from the Society for Neuro-Oncology member survey. Neurooncol Pract 2020;7:38-51. [PMID: 32257283 DOI: 10.1093/nop/npz038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
